NCT01399008 - Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Gout

Interventions

DRUG

Arhalofenate

Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks

DRUG

Allopurinol

Allopurinol 300 mg as active comparator

DRUG

Colchicine

0.6 mg colchicine daily as flare prophylaxis

DRUG

Placebo

Trial Locations (24)

Unknown

Lincoln

Los Angeles

Palo Alto

Boca Raton

Jacksonville

Miami

Honolulu

Baltimore

Brockton

St Louis

Hartsdale

New York

Durham

Cincinnati

San Antonio

West Jordan

Burnaby

St. John's

London

Sarnia

Thornhill

Toronto

Mirabel

Tbilisi